Keywords: promising, ph, iii, data, novartis, lescol, xl
Promising Ph III data with Novartis' Lescol XL
Article | 29 June 2000
Novartis' new extended-release formulation of fluvastatin, LescolXL, has been shown to induce a significant 38% reduction in low-density lipoprotein cholesterol and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
